EFFECTS OF PSILOCYBIN USE IN ADULT PATIENTS WITH ANXIETY AND DEPRESSION: A RAPID REVIEW

Abstract

This protocol proposes to carry out a rapid review of scientific evidence to make evidence-based decisions in health policies and practices. Research on anxiety indicates that approximately 27% of the general population has some type of anxiety disorder. Depression is the most common mental disorder among the population. Globally, it is estimated that more than 300 million people of all ages are affected by this condition. The aim evaluates the safety and efficacy of psilocybin in adult patients with anxiety and depression compared to drug treatment with selective serotonin reuptake inhibitors - SSRIs (fluoxetine, sertraline, fluvoxamine, paroxetine and citalopram), serotonin and norepinephrine reuptake inhibitors - SNRIs (venlafaxine and duloxetine ) and tricyclics (clomipramine). In addition to the association with other antidepressants and cognitive behavioral therapy (CBT).

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Keywords